Business Wire

HCL-TECHNOLOGIES

31.5.2022 13:21:09 CEST | Business Wire | Press release

Share
HCL Technologies Launches X to Power World-Class Digital Engagement for Global Consumer Brands

HCL Technologies (HCL), a leading global technology company, has launched a world-class digital engagement platform, X by HCL Technologies (X), which enables brands to improve consumer loyalty and drive conversions through personalized omnichannel marketing. Research shows only 13% of organizations have a seamlessly integrated marketing and technology stack and brands rely on many different data sources to unlock customer insights. HCL Technologies’ X overcomes these challenges by uniting multiple digital touchpoints, including websites, mobile apps and social media feeds, to create a single view of the consumer. This helps marketers access data-driven insights that enable them to optimize the customer experience and unlock the potential of their brand.

Initially created to underpin Manchester United’s rapidly expanding digital engagement channels, the award-winning platform is now available to help other global brands drive their own success stories by delivering personalized, timely communications and content. Manchester United’s global fanbase has grown with X and the club has experienced a twofold increase in digital engagement with consumers via its website.

Key features and capabilities of the platform include:

  • Publishing: Multilingual content delivery, rich media management, real-time notifications and communication, automated publishing across devices and social channels and audience search and recommendations help brands increase consumer loyalty, through contextual and localized content.
  • Engagement: Brands can activate complex, targeted and personalized campaigns in multiple languages to engage and retain consumer audiences, including gamification through polls and quizzes, loyalty and rewards scheme enablement, social engagement, relationship-building and livestreaming.
  • Conversion: A 360-degree view of the consumer, reduced campaign fragmentation, automated analytics into purchase behavior, measurable KPIs, promotion management and e-commerce integration capabilities enable brands to provide a seamless user experience throughout the customer journey.

“HCL Technologies’ X is a one-stop digital engagement and publishing platform for one of the world’s biggest sports brands and we’re excited to make it available to the wider market,” said Ashish Kumar Gupta, Chief Growth Officer, Europe and Africa, Diversified Industries, HCL Technologies. “The core purpose of X is to create the two-way, in-the-moment engagement that amplifies consumers’ connection with brands and converts users into advocates. Over the last four years, Manchester United’s experience has proven the significant rewards available to organizations that can harness X to drive world-class digital engagement. We look forward to enabling other marketers to use the next-generation capabilities of our platform to improve brand loyalty and optimize revenue growth.”

“The ability to create a two-way digital dialogue with our fans is vital to scaling our brand to a wider global audience,” said Phil Lynch, Chief Executive Officer of Media, Manchester United. “The platform HCL built for us has proven to be the perfect foundation to enable continued growth by providing the insights the club and its partners need to deliver meaningful and personalized content that truly engages our fans. The capabilities the platform provides will ensure we are well-equipped to continue creating compelling brand experiences for our fans long into the future.”

"Anglo American is committed to driving sustainable change for the communities that host us,” said Zaheera Soomar, Global Head of Education, Anglo American. “As part of that goal, we want to ensure all children in our host communities have access to excellent education and training opportunities to reach their true potential. X by HCL Technologies is enabling us to deliver on that promise by creating a world-class student and teacher engagement platform for early years, primary, secondary and post-secondary education in South Africa. This platform has been purpose-built to support students from communities with limited internet connectivity, providing access to more than 2,000 zero-rated and subsidized learning materials and resources. X also enables us to establish a two-way dialogue with those students, bringing us closer to our communities and enabling us to support their education and skills journeys better."

“Digital experiences today are multisensory and context-aware. IDC research finds more than 46% of organizations place customer experience programs as a strategic priority to ensure the business' long-term success. Ultimately, they realize the importance of content in delivering a multi-channel interactive relationship with the consumer,” said Marci Maddox, Research Director, Digital Experience Strategies at IDC. “Traditional approaches to content publishing are becoming obsolete as modern engagement platforms offer organizations multiple entry points into strengthening the relationship with their customers and leveraging technology to automate and personalize digital experiences at scale.”

Link:

ClickThru

Social Media:

https://www.facebook.com/HCLTechnologies

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye